FI3600281T3 - Yhdistelmähoito kasvainten hoitoa tai ehkäisemistä varten - Google Patents

Yhdistelmähoito kasvainten hoitoa tai ehkäisemistä varten Download PDF

Info

Publication number
FI3600281T3
FI3600281T3 FIEP18770812.8T FI18770812T FI3600281T3 FI 3600281 T3 FI3600281 T3 FI 3600281T3 FI 18770812 T FI18770812 T FI 18770812T FI 3600281 T3 FI3600281 T3 FI 3600281T3
Authority
FI
Finland
Prior art keywords
alkyl
alkynyl
alkenyl
compound
immune response
Prior art date
Application number
FIEP18770812.8T
Other languages
English (en)
Finnish (fi)
Inventor
Paul Warren Reddell
Jason Kingsley Cullen
Glen Mathew Boyle
Peter Gordon Parsons
Victoria Anne Gordon
Original Assignee
QBiotics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901027A external-priority patent/AU2017901027A0/en
Application filed by QBiotics Pty Ltd filed Critical QBiotics Pty Ltd
Application granted granted Critical
Publication of FI3600281T3 publication Critical patent/FI3600281T3/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FIEP18770812.8T 2017-03-23 2018-03-23 Yhdistelmähoito kasvainten hoitoa tai ehkäisemistä varten FI3600281T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017901027A AU2017901027A0 (en) 2017-03-23 Combination Therapy
PCT/AU2018/050277 WO2018170559A1 (en) 2017-03-23 2018-03-23 Combination therapy for the treatment or prevention of tumours

Publications (1)

Publication Number Publication Date
FI3600281T3 true FI3600281T3 (fi) 2023-08-24

Family

ID=63583892

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18770812.8T FI3600281T3 (fi) 2017-03-23 2018-03-23 Yhdistelmähoito kasvainten hoitoa tai ehkäisemistä varten

Country Status (27)

Country Link
US (1) US11213506B2 (https=)
EP (1) EP3600281B1 (https=)
JP (1) JP6905075B2 (https=)
KR (1) KR102228055B1 (https=)
CN (1) CN110461324A (https=)
AU (1) AU2018238202C1 (https=)
CA (1) CA3056685C (https=)
DK (1) DK3600281T3 (https=)
EA (1) EA201992220A1 (https=)
ES (1) ES2953575T3 (https=)
FI (1) FI3600281T3 (https=)
HR (1) HRP20230936T1 (https=)
HU (1) HUE063299T2 (https=)
IL (1) IL269522B2 (https=)
LT (1) LT3600281T (https=)
MX (1) MX391826B (https=)
MY (1) MY197427A (https=)
PH (1) PH12019502132A1 (https=)
PL (1) PL3600281T3 (https=)
PT (1) PT3600281T (https=)
RS (1) RS64472B1 (https=)
SG (1) SG11201907891XA (https=)
SI (1) SI3600281T1 (https=)
SM (1) SMT202300272T1 (https=)
UA (1) UA125614C2 (https=)
WO (1) WO2018170559A1 (https=)
ZA (1) ZA201906001B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006326872C1 (en) * 2005-12-23 2018-05-17 QBiotics Pty Ltd Tiglien-3-one derivatives
TWI707038B (zh) 2013-08-05 2020-10-11 美商扭轉生物科技有限公司 重新合成之基因庫
WO2016126882A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
KR20180050411A (ko) 2015-09-18 2018-05-14 트위스트 바이오사이언스 코포레이션 올리고핵산 변이체 라이브러리 및 그의 합성
KR102794025B1 (ko) 2015-09-22 2025-04-09 트위스트 바이오사이언스 코포레이션 핵산 합성을 위한 가요성 기판
US10417457B2 (en) 2016-09-21 2019-09-17 Twist Bioscience Corporation Nucleic acid based data storage
CN110892485B (zh) 2017-02-22 2024-03-22 特韦斯特生物科学公司 基于核酸的数据存储
US10696965B2 (en) 2017-06-12 2020-06-30 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
CN111566125A (zh) 2017-09-11 2020-08-21 特韦斯特生物科学公司 Gpcr结合蛋白及其合成
CN111565834B (zh) 2017-10-20 2022-08-26 特韦斯特生物科学公司 用于多核苷酸合成的加热的纳米孔
KR102804057B1 (ko) 2018-01-04 2025-05-07 트위스트 바이오사이언스 코포레이션 Dna 기반 디지털 정보 저장
CA3100739A1 (en) 2018-05-18 2019-11-21 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
US12357959B2 (en) 2018-12-26 2025-07-15 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
CA3131691A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
CN113766930B (zh) 2019-02-26 2025-07-22 特韦斯特生物科学公司 Glp1受体的变异核酸文库
EP3952858B1 (en) * 2019-04-12 2025-12-17 QBiotics Pty Ltd Method of treating tumours
MX2021015673A (es) 2019-06-19 2022-02-03 QBiotics Pty Ltd Alteracion de biopelicula.
AU2020298294A1 (en) 2019-06-21 2022-02-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
JP2022548309A (ja) 2019-09-23 2022-11-17 ツイスト バイオサイエンス コーポレーション Crth2のバリアント核酸ライブラリー
WO2021061842A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for single domain antibodies
IL293670A (en) 2019-12-09 2022-08-01 Twist Bioscience Corp Variable nucleic acid libraries for adenosine receptors
WO2022159620A1 (en) 2021-01-21 2022-07-28 Twist Bioscience Corporation Methods and compositions relating to adenosine receptors
KR102774792B1 (ko) 2021-05-06 2025-03-05 한국과학기술연구원 가시광선에 의해 활성화되는 항암 면역치료용 나노입자 및 이의 용도
CN118451065A (zh) * 2021-12-21 2024-08-06 Q生物股份有限公司 结晶中间体
MX2024010046A (es) * 2022-02-17 2024-08-26 QBiotics Pty Ltd Terapias de combinacion.
JP2026500534A (ja) * 2022-12-21 2026-01-07 キューバイオティクス プロプライアタリー リミティド 結晶形態及びその製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006268148B2 (en) * 2005-07-13 2012-11-01 Salvia Sciences, Inc. Ester prodrugs of prostratin and related phorbol compounds
AU2006326872C1 (en) * 2005-12-23 2018-05-17 QBiotics Pty Ltd Tiglien-3-one derivatives
RS58532B1 (sr) 2013-04-18 2019-04-30 Qbiotics Ltd Metodi i kompozicije za zarastanje rana
WO2015133596A1 (ja) * 2014-03-07 2015-09-11 国立大学法人京都大学 細胞培養用組成物
AU2015289081B2 (en) 2014-07-16 2020-02-06 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
JP6991857B2 (ja) 2014-10-10 2022-01-13 イデラ ファーマシューティカルズ インコーポレイテッド Tlr9アゴニストをチェックポイント阻害剤と共に用いるがんの治療
CN104926758A (zh) * 2015-05-22 2015-09-23 南京泽朗医药科技有限公司 斑籽素的制备方法及其在抗白血病药物中的应用
CN108026026B (zh) * 2015-08-03 2021-02-09 夸德里加生物科学公司 作为化疗剂的β-取代的β-氨基酸和类似物及其应用

Also Published As

Publication number Publication date
IL269522A (https=) 2019-11-28
ES2953575T3 (es) 2023-11-14
MX2019011221A (es) 2019-11-01
NZ756754A (en) 2024-02-23
HRP20230936T1 (hr) 2023-11-24
AU2018238202C1 (en) 2025-06-05
PL3600281T3 (pl) 2023-09-11
CA3056685A1 (en) 2018-09-27
UA125614C2 (uk) 2022-05-04
CN110461324A (zh) 2019-11-15
EP3600281A1 (en) 2020-02-05
AU2018238202A8 (en) 2024-03-28
KR102228055B1 (ko) 2021-03-16
RS64472B1 (sr) 2023-09-29
AU2018238202B2 (en) 2024-03-28
SG11201907891XA (en) 2019-09-27
US20200030279A1 (en) 2020-01-30
SI3600281T1 (sl) 2023-10-30
ZA201906001B (en) 2023-12-20
WO2018170559A1 (en) 2018-09-27
JP2020511512A (ja) 2020-04-16
CA3056685C (en) 2024-01-16
MY197427A (en) 2023-06-16
DK3600281T3 (da) 2023-08-14
IL269522B1 (en) 2024-01-01
HUE063299T2 (hu) 2024-01-28
PT3600281T (pt) 2023-09-04
EP3600281A4 (en) 2020-03-18
SMT202300272T1 (it) 2023-09-06
EP3600281B1 (en) 2023-05-31
KR20190126431A (ko) 2019-11-11
US11213506B2 (en) 2022-01-04
EA201992220A1 (ru) 2020-02-11
LT3600281T (lt) 2023-09-11
MX391826B (es) 2025-03-21
JP6905075B2 (ja) 2021-07-21
PH12019502132A1 (en) 2020-07-06
AU2018238202A1 (en) 2019-09-19
IL269522B2 (en) 2024-05-01
BR112019019748A2 (pt) 2020-04-14

Similar Documents

Publication Publication Date Title
FI3600281T3 (fi) Yhdistelmähoito kasvainten hoitoa tai ehkäisemistä varten
CO2022008997A2 (es) Compuestos tricíclicos sustituidos
CO2022010460A2 (es) Compuestos tricíclicos sustituidos
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
US20190262312A1 (en) Compounds and methods to sensitize cancer cells to cisplatin
JP2017528524A5 (https=)
DOP2021000077A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
MX2023014754A (es) Métodos y composiciones dirigidos a pd-l1.
US11911348B2 (en) Therapeutic agent for cancer
AR089019A1 (es) Derivados modificados de 4-fenil-piridina
JP2013527243A5 (https=)
AR101177A1 (es) Inhibidores de la syk
SG11202111402PA (en) Anti-cancer nuclear hormone receptor-targeting compounds
RU2011133128A (ru) Противоопухолевые соединения дигидропиран-2-она
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
MX2018013325A (es) Derivados de adenina como inhibidores de proteína quinasa.
CO2021017202A2 (es) Compuestos tricíclicos
JP2017515899A5 (https=)
RU2011139157A (ru) Производное трициклического пиразолопиримидина
JP2018526320A5 (https=)
CN107921135A (zh) 噻吩并吡啶化合物的混合二硫共轭物及其用法
EA201792087A1 (ru) ПРОИЗВОДНЫЕ 7-(МОРФОЛИН-4-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИМИДИНА, ПРИГОДНЫЕ ДЛЯ ЛЕЧЕНИЯ ИММУННЫХ ИЛИ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ИЛИ РАКА
Castelli et al. Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma
AR058329A1 (es) Derivados de pirazolo (4,3-c) piridina sustituidos activos como inhibidores de quinasa, un metodo para su preparacion y composicion farmaceutica